ArticleThe Cochrane database of systematic reviews2026

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

Anneloes Noordhof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.